Scholars Central

ArticlePublished 3 Feb 2012

Formulation of oral iron chelator deferasirox in a new stable and suitable dosage form with optimum release parameters.

Authors: Yugandhar K. M., Vasanth P. M., Suresh K., Ramesh T., Ramesh Malothu

International Journal of Bioassays

Volume 2 · Issue 2 · Pages 469–474

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Regular blood transfusions for patients with chronic anemia inevitably lead to iron overload in the blood. The cumulative effect of iron overload may cause morbidity and mortality if not treated with chelator. Oral iron chelator, Deferasirox used in the treatment of β-thalessemia is designed and developed into a stable solid oral dispersion dosage form to deliver with optimum concentration of the drug at desired site at specific time comparable to the innovator product. The excipients were formulated by direct compression method (F-1) and wet granulation method (F-2 to F-9). The disintegration time (33 seconds), dispersion time (62 seconds) and the percentage of drug release (98.3%) (F-8) were found to be satisfactory and it matches with the innovator product.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in International Journal of Bioassays.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Bioassays
  • SubjectDentistry & Oral Health
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Yugandhar K. M.”
  • BylineArticles whose byline prints “Vasanth P. M.”
  • BylineArticles whose byline prints “Suresh K.”
  • BylineArticles whose byline prints “Ramesh T.”
  • BylineArticles whose byline prints “Ramesh Malothu”